Canaccord Genuity Group Reiterates “Buy” Rating for BioNTech (NASDAQ:BNTX)

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating reaffirmed by analysts at Canaccord Genuity Group in a note issued to investors on Wednesday,Benzinga reports. They currently have a $171.00 price target on the stock. Canaccord Genuity Group’s price target points to a potential upside of 89.79% from the stock’s previous close.

BNTX has been the topic of several other reports. Bank of America reaffirmed a “buy” rating and issued a $128.00 price target on shares of BioNTech in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $140.00 target price on shares of BioNTech in a research report on Thursday, December 11th. Citigroup reduced their price target on shares of BioNTech from $145.00 to $130.00 and set a “buy” rating for the company in a report on Wednesday. BMO Capital Markets dropped their price objective on shares of BioNTech from $143.00 to $128.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, Leerink Partners lowered shares of BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price objective for the company. in a research report on Monday, February 2nd. Twelve equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, BioNTech currently has an average rating of “Moderate Buy” and a consensus price target of $133.73.

BioNTech Stock Down 0.8%

BNTX opened at $90.10 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.02 and a current ratio of 7.54. The business has a 50 day moving average price of $106.54 and a 200 day moving average price of $102.66. The firm has a market cap of $20.29 billion, a P/E ratio of -17.19 and a beta of 1.51. BioNTech has a twelve month low of $79.52 and a twelve month high of $124.00.

Institutional Trading of BioNTech

A number of large investors have recently bought and sold shares of the stock. Larson Financial Group LLC raised its stake in BioNTech by 86.4% during the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after acquiring an additional 127 shares in the last quarter. EFG International AG acquired a new stake in shares of BioNTech in the 4th quarter valued at $29,000. Caitong International Asset Management Co. Ltd grew its holdings in shares of BioNTech by 520.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock worth $30,000 after purchasing an additional 260 shares during the last quarter. Financial Consulate Inc. acquired a new stake in shares of BioNTech during the 3rd quarter worth about $36,000. Finally, Huntington National Bank lifted its holdings in BioNTech by 1,266.7% during the 3rd quarter. Huntington National Bank now owns 410 shares of the company’s stock valued at $40,000 after purchasing an additional 380 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors.

BioNTech News Summary

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Canaccord reiterated a “buy” rating and set a high $171 price target, signaling strong upside relative to the current level and supporting bullish investor thesis on long‑term mRNA opportunity. Canaccord reaffirms buy, $171 PT
• Positive Sentiment: Goldman Sachs reaffirmed its “buy” rating, providing another institutional vote of confidence that may stabilize sentiment among growth‑oriented holders. Goldman Sachs reaffirms buy
• Positive Sentiment: BioNTech and its co‑founders announced plans to pursue next‑generation mRNA innovations — a strategic signal that the company is investing in future product pipelines beyond COVID vaccines. Co‑founders pursue next‑gen mRNA
• Neutral Sentiment: Independent write‑ups are debating whether recent weakness makes BNTX a value play; the analysis highlights multi‑period share declines but leaves valuation conclusions to readers. Yahoo analysis on BNTX valuation
• Neutral Sentiment: Data feeds flagged a “large increase” in short interest, but the published figures are inconsistent (zeros/NaN and 0.0 days to cover), suggesting a likely reporting glitch rather than actionable short‑squeeze pressure.
• Neutral Sentiment: BMO trimmed its price target (to $128) but kept an “outperform” stance — a modest downgrade in optimism rather than a rout. BMO lowers PT to $128
• Negative Sentiment: Several outlets reported a steep share drop after an earnings miss and leadership changes (founder departures); that combination typically triggers near‑term selling and raises execution risk. Earnings miss & founder exodus — Blockonomi Earnings miss & leadership change — Tokenist
• Negative Sentiment: Multiple sell‑side revisions trimmed expectations: Citigroup lowered its PT to $130 (still a “buy”), TD Cowen cut to $94 and moved to “hold”, and Jefferies published more cautious forecasts — collectively cooling near‑term analyst enthusiasm. Citigroup cuts PT to $130 TD Cowen cuts to $94 Jefferies lowers expectations

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.